Drug Trial Radar · NCT02503033
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
78
Planned (sponsor's estimate)
Start
Nov 2015
Primary completion
Dec 2020
Study completion Mar 2021
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Jul 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory Hematologic Malignancies To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the dose limited toxicities associated with HMPL-523 when administered to patients with relapsed or refractory Hematologic Malignancies
Conditions
- Hematologic Malignancies
Interventions
HMPL-523Drug
Oral administration, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- dose limited toxicities evaluated with NCI CTCAE v4.03Time frame: within 28days after the first dose
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Border Medical Oncology Research Unit
Albury, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Townsville Hospital
Townsville, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Ballarat Regional Integrated Cancer Centre
Ballarat, Victoria, Australia
St Vincent's Hospital
Fitzroy, Victoria, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Barwon Health
Geelong, Victoria, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Cabrini Health
Melbourne, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.